Herantis Pharma (Finland) Performance
| HRTIS Stock | EUR 1.49 0.07 4.49% |
Herantis Pharma has a performance score of 4 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of -0.2, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Herantis Pharma are expected to decrease at a much lower rate. During the bear market, Herantis Pharma is likely to outperform the market. Herantis Pharma Oyj right now retains a risk of 2.82%. Please check out Herantis Pharma value at risk, as well as the relationship between the skewness and day median price , to decide if Herantis Pharma will be following its current trending patterns.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Herantis Pharma Oyj are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite fairly inconsistent technical indicators, Herantis Pharma may actually be approaching a critical reversion point that can send shares even higher in January 2025. ...more
| Begin Period Cash Flow | 13.3 M |
Herantis |
Herantis Pharma Relative Risk vs. Return Landscape
If you would invest 144.00 in Herantis Pharma Oyj on September 28, 2024 and sell it today you would earn a total of 12.00 from holding Herantis Pharma Oyj or generate 8.33% return on investment over 90 days. Herantis Pharma Oyj is generating 0.1699% of daily returns and assumes 2.8151% volatility on return distribution over the 90 days horizon. Simply put, 25% of stocks are less volatile than Herantis, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Herantis Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Herantis Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Herantis Pharma Oyj, and traders can use it to determine the average amount a Herantis Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0604
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | HRTIS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.82 actual daily | 25 75% of assets are more volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Herantis Pharma is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Herantis Pharma by adding it to a well-diversified portfolio.
Herantis Pharma Fundamentals Growth
Herantis Stock prices reflect investors' perceptions of the future prospects and financial health of Herantis Pharma, and Herantis Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Herantis Stock performance.
| Return On Equity | -13.37 | |||
| Return On Asset | -0.6 | |||
| Current Valuation | 25.86 M | |||
| Shares Outstanding | 16.91 M | |||
| Price To Earning | (7.20) X | |||
| Price To Book | 15.17 X | |||
| EBITDA | (9.74 M) | |||
| Cash And Equivalents | 7.86 M | |||
| Cash Per Share | 0.81 X | |||
| Total Debt | 6.29 M | |||
| Debt To Equity | 0.95 % | |||
| Book Value Per Share | 0.11 X | |||
| Cash Flow From Operations | (9.93 M) | |||
| Earnings Per Share | (1.25) X | |||
| Total Asset | 7.76 M | |||
| Retained Earnings | (27 M) | |||
| Current Asset | 6 M | |||
| Current Liabilities | 1000 K | |||
About Herantis Pharma Performance
By evaluating Herantis Pharma's fundamental ratios, stakeholders can gain valuable insights into Herantis Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Herantis Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Herantis Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Herantis Pharma Oyj, a drug development company, focuses on developing regenerative therapeutics. The company was founded in 2008 and is based in Espoo, Finland. Herantis Pharma operates under Pharmaceuticals And Biosciences classification in Finland and is traded on Helsinki Exchange. It employs 13 people.Things to note about Herantis Pharma Oyj performance evaluation
Checking the ongoing alerts about Herantis Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Herantis Pharma Oyj help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Herantis Pharma Oyj may become a speculative penny stock | |
| Herantis Pharma Oyj has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (12.77 M) with profit before overhead, payroll, taxes, and interest of 90 K. | |
| Herantis Pharma Oyj has accumulated about 7.86 M in cash with (9.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81. | |
| Roughly 32.0% of the company shares are held by company insiders |
- Analyzing Herantis Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Herantis Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Herantis Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Herantis Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Herantis Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Herantis Pharma's stock. These opinions can provide insight into Herantis Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Herantis Stock analysis
When running Herantis Pharma's price analysis, check to measure Herantis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Herantis Pharma is operating at the current time. Most of Herantis Pharma's value examination focuses on studying past and present price action to predict the probability of Herantis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Herantis Pharma's price. Additionally, you may evaluate how the addition of Herantis Pharma to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |